These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31934611)

  • 1. Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.
    Harris JP; Burrell JC; Struzyna LA; Chen HI; Serruya MD; Wolf JA; Duda JE; Cullen DK
    NPJ Parkinsons Dis; 2020; 6():4. PubMed ID: 31934611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson's Disease.
    Struzyna LA; Browne KD; Burrell JC; Vélez WJG; Wofford KL; Kaplan HM; Murthy NS; Chen HI; Duda JE; España RA; Cullen DK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
    Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria.
    Gordián-Vélez WJ; Chouhan D; España RA; Chen HI; Burdick JA; Duda JE; Cullen DK
    Brain Res Bull; 2021 Oct; 175():168-185. PubMed ID: 34332016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Levivier M; Przedborski S; Bencsics C; Kang UJ
    J Neurosci; 1995 Dec; 15(12):7810-20. PubMed ID: 8613721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinson's disease.
    Błaszczyk JW
    Acta Neurobiol Exp (Wars); 2017; 77(1):106-112. PubMed ID: 28379221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regenerative Therapies for Parkinson's Disease: An Update.
    Stoker TB; Barker RA
    BioDrugs; 2018 Aug; 32(4):357-366. PubMed ID: 30027398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cells and regenerative therapies for Parkinson's disease.
    Farrell K; Barker RA
    Degener Neurol Neuromuscul Dis; 2012; 2():79-92. PubMed ID: 30890881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Therapy for Parkinson's Disease.
    Shastry S; Hu J; Ying M; Mao X
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38139997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
    Glavaski-Joksimovic A; Bohn MC
    Exp Neurol; 2013 Sep; 247():25-38. PubMed ID: 23542820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.
    Cui YF; Hargus G; Xu JC; Schmid JS; Shen YQ; Glatzel M; Schachner M; Bernreuther C
    Brain; 2010 Jan; 133(Pt 1):189-204. PubMed ID: 19995872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell transplantation in the damaged adult brain.
    Jaber M; Benoit-Marand M; Prestoz L; Gaillard A
    Rev Neurol (Paris); 2013 Nov; 169(11):838-43. PubMed ID: 24112517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
    Isacson O; Bjorklund LM; Schumacher JM
    Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.